Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.45 |
| ▸ | TLK2 | Q86UE8 | 6/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | NEK2 | P51955 | 2/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5368073 | 0.89 | PDPK1 (0.61) | PDPK1AURKARAF1GSK3BCDK1 | |
| SCHEMBL14519109 | 0.85 | TLK2 (0.57) | PDPK1KDRCDK1CCNB1TLK2 | |
| SCHEMBL5364974 | 0.81 | PDPK1 (0.46) | PDPK1AURKARAF1EGFRCDK1 | |
| SCHEMBL5362148 | 0.80 | KDR (0.48) | PDPK1AURKARAF1KDRGSK3B | |
| SCHEMBL5359077 | 0.78 | EGFR (0.47) | PDPK1KDREGFR | |
| SCHEMBL5374151 | 0.78 | PDPK1 (0.78) | PDPK1KDRCDK1CCNB1TLK2 | |
| SCHEMBL5369648 | 0.78 | TLK2 (0.74) | PDPK1AURKAKDRTLK2ABL1 | |
| SCHEMBL5366834 | 0.78 | GSK3B (0.52) | KDRGSK3BEGFRTLK2PDGFRB | |
| SCHEMBL5370079 | 0.78 | PAK4 (0.51) | KDRGSK3BPDGFRBPAK4 | |
| SCHEMBL5358237 | 0.77 | LRRK2 (0.44) | PDPK1AURKAKDRGSK3BEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
| EP-1247803-A2 | Indolinone compounds suitable for modulation of protein kinases | Sugen, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | PDPK1 31/4885AURKA 181/4885RAF1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.